FDA approves first therapy for high-risk neuroblastoma
On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma.…
News
FDA launches drug shortages app
On March 4, the U.S. Food and Drug Administration (FDA) launched a free mobile app that identifies current drug shortages, resolved shortages, and discontinuations…
FDA approves system to permanently treat varicose veins
On February 20, the U.S. Food and Drug Administration (FDA) approved he VenaSeal closure system (VenaSeal system) to permanently treat varicose veins of the…
FDA approves Farydak for treatment of multiple myeloma
On February 23, the U.S. Food and Drug Administration (FDA) approved Farydak (panobinostat) for the treatment of patients with multiple myeloma. Read more.
FDA approves new drug for thyroid cancer
On February 13, the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer whose disease progressed…
FDA approves Lucentis to treat diabetic retinopathy
On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy…
FDA approves first generic version of Nexium
On January 26, the U.S. Food and Drug Administration (FDA) approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules) to treat gastroesophageal…
FDA permits marking of mobile app for glucose monitoring
On January 23, the U.S. Food and Drug Administration (FDA) permitted marketing of the first set of mobile medical apps that allow people with…
FDA approves Ibrance for postmenopausal women with metastatic breast cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
FDA approves first therapy for high-risk neuroblastoma
On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with…
FDA launches drug shortages app
On March 4, the U.S. Food and Drug Administration (FDA) launched a free mobile app that identifies current drug shortages, resolved shortages,…
FDA approves system to permanently treat varicose veins
On February 20, the U.S. Food and Drug Administration (FDA) approved he VenaSeal closure system (VenaSeal system) to permanently treat varicose veins…
FDA approves Farydak for treatment of multiple myeloma
On February 23, the U.S. Food and Drug Administration (FDA) approved Farydak (panobinostat) for the treatment of patients with multiple myeloma. Read…
FDA approves new drug for thyroid cancer
On February 13, the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer whose…
FDA approves Lucentis to treat diabetic retinopathy
On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat…
FDA approves first generic version of Nexium
On January 26, the U.S. Food and Drug Administration (FDA) approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules) to…
FDA permits marking of mobile app for glucose monitoring
On January 23, the U.S. Food and Drug Administration (FDA) permitted marketing of the first set of mobile medical apps that allow…
FDA approves Ibrance for postmenopausal women with metastatic breast cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
Poll
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.